ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Group (NYSE: CRA), an Applera Corporation business, today reported revenues of $16.1 million for the first quarter of fiscal 2008, compared to $10.2 million in the prior year quarter. The first quarter fiscal 2008 results included $5.0 million of net revenues related to the achievement of a drug development license milestone by a third party and the resale of a small molecule drug development program as described under Financial Highlights below. For the first quarter of fiscal 2008, Celera reported net income of $0.7 million, or $0.01 per share, compared to a net loss of $7.1 million, or $0.09 per share, for the prior year quarter. The first quarter fiscal 2007 results included a pre-tax charge of $3.5 million for Celera’s estimated share of a damage award in continuing litigation between Abbott Laboratories, Celera’s alliance partner, and Innogenetics N.V. All per share amounts refer to Applera Corporation-Celera Group Common Stock.
